OXS-1550 / GT Biopharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OXS-1550 / GT Biopharma
NCT02370160: HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Checkmark Final results
May 2019 - May 2019: Final results
Checkmark Preliminary data from NHL & ALL patients
Jun 2018 - Jun 2018: Preliminary data from NHL & ALL patients
Completed
1/2
18
US
DT2219ARL
Masonic Cancer Center, University of Minnesota
Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma
04/18
04/18

Download Options